Our study provides the first evidence that the CXCL12/CXCR4/FOLR1 axis is associated with sorafenib resistance in HCC, suggesting a potential new target for improving the efficacy of sorafenib and the prognosis of HCC patients. Here, FOLR1 is linked to hepatocellular carcinoma.